FDA Rejects AcelRx’s Drug-Device Pain Product; Asks for More Bench Testing, Better IFU

Drug Industry Daily
A A
The FDA has rejected specialty drugmaker AcelRx Phaemaceuticals’ NDA for Zalviso, a drug-device combination product to treat pain.

To View This Article:

Login

Subscribe To Drug Industry Daily